AXSM
Axsome Therapeutics Hits Milestone: FDA Approval of Auvelity for Alzheimer's Disease Agitation
On a recent conference call, Axsome Therapeutics reported strong year-over-year growth across its business in the first quarter of 2026. The company's commercial products and advancing research and development pipeline were key drivers behind this performance. Total revenue from Axsome's three marketed products reached $191 million,